Current Cancer Therapy Reviews
Title:Meet Our Editorial Board Member
Volume: 12 Issue: 3
Author(s): Carl-Henrik Heldin
Affiliation:
Export Options
About this article
Cite this article as:
Heldin Carl-Henrik, Meet Our Editorial Board Member, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/157339471203170208191110
DOI https://dx.doi.org/10.2174/157339471203170208191110 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
14
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Killer Cells: Prospects in Cancer Immunotherapy
Current Immunology Reviews (Discontinued) Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Impact of Opioids on Cardiac Electrophysiology
Current Cardiology Reviews The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine Up-regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Letters in Drug Design & Discovery Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry